Author:
Sun Chunbin,Zhang Jin,Hou Jiong,Hui Menglin,Qi Hualong,Lei Tong,Zhang Xiaoshuang,Zhao Luxi,Du Hongwu
Subject
Pharmacology,General Medicine
Reference36 articles.
1. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis;Qing;Lancet Gastroenterol. Hepatol.,2020
2. Lack of VMP1 impairs hepatic lipoprotein secretion and promotes non-alcoholic steatohepatitis;Jiang;J. Hepatol.,2022
3. Metformin treatment rescues CD8+ T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD;Wabitsch;J. Hepatol.,2022
4. A. nonalcoholic steatohepatitis (NASH)-current treatment recommendations and future developments;Roeb;Z. Gastroenterol.,2019
5. Time to transition from a negative nomenclature describing what NAFLD is not, to a novel, pathophysiology-based, umbrella classification of fatty liver disease (FLD);Valenzuela-Vallejo;Metabolism,2022
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献